HER2 Breast Cancer

Study data show that extended endocrine therapy after 5 years reduces late recurrence in premenopausal breast cancer, with benefits varying by tumor subtype.

AACR data show tumor molecular profiling finds actionable PIK3CA in breast and colorectal cancer, while ctDNA adds real-time monitoring in oncology.

There is an increasing interest in de-escalation strategies for HER2-positive breast cancer aimed at decreasing toxicity exposure while maintaining efficacy.

Air pollution exposure, particularly fine particulate matter and ozone, may worsen cardiac outcomes in patients with breast cancer receiving cardiotoxic therapies.

Circulating tumor DNA detected after neoadjuvant therapy may serve as a powerful biomarker for minimal residual disease and help predict breast cancer recurrence.

Tucatinib triplet regimen with trastuzumab and capecitabine boosts survival and cerebrospinal fluid control in HER2-positive breast cancer leptomeningeal metastasis.

ADCs are reshaping metastatic breast cancer and pharmacists' roles in treatment management.

Oral bacteria such as Fusobacterium nucleatum may fuel breast cancer. Here's what pharmacists should know about periodontal health and genetic risk.

HER2 breast cancer vaccine boosted by CD27 sparked durable CD4 memory and dramatic tumor regression in studies.

Expanded Medicaid coverage has been linked to access to early diagnosis, timely treatment, and continuity of care in breast cancer.

NCCN-backed MammaPrint stratifies HR+ breast cancer, pinpointing who needs anthracyclines and how pharmacists help personalize oncology care.

NCCN updates can guide pharmacists to tailor chemotherapy for HR+/HER2- breast cancer using MammaPrint and FLEX survival data.

Dato-DXd is a promising first-line treatment for metastatic triple-negative breast cancer, enhancing patient outcomes.

FDA grants priority review for gedatolisib, a promising treatment for advanced HR+/HER2– breast cancer, showcasing significant efficacy in recent trials.

Sacituzumab govitecan shows promising overall survival trends in HR+/HER2− metastatic breast cancer, despite not meeting primary progression-free survival goals.

Fam-trastuzumab deruxtecan-nxki (T-DXd) promises enhanced outcomes for HER2-positive early breast cancer patients post-neoadjuvant treatment.

Ribociclib shows higher early treatment modifications than palbociclib in HR+/HER2– breast cancer, emphasizing the need for proactive toxicity management.

The approval is supported by findings from the phase 3 DESTINY-Breast09 trial.

Explore the HER2CLIMB-05 study's findings on tucatinib's impact on breast cancer progression-free survival, enhancing treatment options for pharmacists.

Discover how the combination of palbociclib, trastuzumab, and endocrine therapy enhances survival in HER2-positive advanced breast cancer patients.

CAR T-cell therapy shows promise for treating HER2-positive breast cancer with CNS metastases, offering a novel approach to improve patient outcomes.

Advanced IHC assays enhance HER2-low breast cancer detection, improving treatment eligibility for trastuzumab deruxtecan.